GLP1R and type 2 diabetes mellitus: In the Harmony Outcomes study, albiglutide outperformed placebo in terms of serious adverse cardiovascular problems in people with type 2 diabetes and cardiovascular morbidities with a hazard ratio of 0.78, which implies that GLP-1 agonists can improve cardiovascular outcomes according to these data [31].